Clinical Trial Update: Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tivantinib plus cetuximab in EGFR inhibitor-resistant, MET-high metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• tivantinib (tivantinib)

Snippet

Sponsor: Armando Santoro, MD | Conditions: Colorectal Cancer Metastatic, C-met Overexpression | Phase 2 | Status: COMPLETED